Osteopromotion with a plasmatransglutaminase on a beta-TCP ceramic.
We investigated the osteopromotive properties of plasmatransglutaminase (F XIII), bone marrow and venous blood on a resorbable beta-tricalcium phosphate (beta-TCP) scaffold. A baseline binding and release study of F XIII from the scaffold showed a continuous release of 18% of the total dose after 48 h. The main study consisted of 18 adult sheep with cylindrical defects in both tibiae. The defects were filled with a beta-TCP cylinder impregnated either with bone marrow, venous blood, F XIII or sheep were treated with 1250 IU F XIII intravenously over 14 days (n = 4 in each group). The defects were left open in two sheep. QCT and histology was performed after 6 and 12 weeks. The best bone ingrowth was seen after 6 weeks in the bone marrow group and after 12 weeks in the local F XIII group. The highest ingrowth on the inside of the cylinder proving the osteopromoting potential of F XIII was found in the local F XIII group. In our opinion F XIII is a good and readily available osteopromoting agent which can be used with beta-TCP in cases of bone deficit to promote bone regeneration.
Becker
Stephan
S
Spine Center, Orthopedic Hospital Speising, Speisinger Str. 109, Vienna, Austria. stephan.becker@oss.at
Maissen
Otto
O
Ponomarev
Igor
I
Stoll
Thierry
T
Meury
Thomas
T
Sprecher
Christoph
C
Alini
Mauro
M
Wilke
Ingo
I
D000818:Animals; D001672:Biocompatible Materials; D001846:Bone Development / Q000502:physiology*; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D018786:Bone Substitutes; D002130:Calcium Phosphates / Q000737:chemistry*; D002516:Ceramics / Q000737:chemistry*; D026122:Factor XIIIa / Q000378:metabolism*; D006614:Hindlimb; D012756:Sheep; D013977:Tibia; D054457:Tissue Scaffolds
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D026122:Factor XIIIa